RWA Wealth Partners LLC Has $2.48 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

RWA Wealth Partners LLC decreased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,833 shares of the company’s stock after selling 1,792 shares during the period. RWA Wealth Partners LLC’s holdings in AstraZeneca were worth $2,479,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Cibc World Markets Corp lifted its position in shares of AstraZeneca by 1.1% during the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock worth $845,000 after purchasing an additional 142 shares in the last quarter. Diversify Wealth Management LLC lifted its holdings in AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after buying an additional 153 shares in the last quarter. Veery Capital LLC boosted its position in AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after buying an additional 157 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in AstraZeneca by 1.8% in the 3rd quarter. Rehmann Capital Advisory Group now owns 10,027 shares of the company’s stock valued at $788,000 after buying an additional 175 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its stake in shares of AstraZeneca by 0.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock valued at $2,313,000 after buying an additional 189 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 1.3 %

NASDAQ:AZN opened at $73.79 on Monday. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 1-year low of $62.75 and a 1-year high of $87.68. The firm has a market capitalization of $228.84 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 1.42 and a beta of 0.41. The business’s 50-day moving average price is $73.55 and its two-hundred day moving average price is $71.61.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, March 24th. Stockholders of record on Friday, February 21st were given a dividend of $1.03 per share. This represents a dividend yield of 2%. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend was Friday, February 21st. AstraZeneca’s dividend payout ratio (DPR) is currently 91.15%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Morgan Stanley started coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock. UBS Group upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.